Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that enhances insulin secretion and inhibits glucagon release in response to elevated glucose levels. By slowing gastric emptying and regulating energy balance, it supports more stable glucose utilization and reduces fluctuations in energy intake. Additionally, Semaglutide’s prolonged half-life allows for sustained activation of GLP-1 receptors, improving metabolic efficiency over time.